D-2570 clinical trials
How each study uses D-2570 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the D-2570 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
13 studies that test it; most in 2026 (8)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7, 2 in phase 3
Studies that test D-2570, phase 3 first.
- Jul 2027A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque PsoriasisPhase 3 · InventisBio Co., Ltd
- Jul 2027Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque PsoriasisPhase 3 · InventisBio Co., Ltd
- Nov 2026The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.Phase 1 · InventisBio Co., Ltd
- Dec 2026A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy AdultsPhase 1 · InventisBio Co., Ltd
- Aug 2027A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque PsoriasisPhase 2 · InventisBio Co., Ltd
- Aug 2027A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic ArthritisPhase 2 · InventisBio Co., Ltd
- Nov 2027Study of D-2570 in Subjects With Non-Segmental VitiligoPhase 2 · InventisBio Co., Ltd
Studies
Open first, then newest update. How each study uses D-2570 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy AdultsNot yet recruitingPhase 1InventisBio Co., LtdNCT07875842Written as D-2570
- The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.RecruitingPhase 1InventisBio Co., LtdNCT07715175Written as D-2570
- A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic FunctionRecruitingPhase 1InventisBio Co., LtdNCT07715149Written as D-2570
- Study of D-2570 in Subjects With Non-Segmental VitiligoRecruitingPhase 2InventisBio Co., LtdNCT07625891Written as D-2570 Dose 1
- A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque PsoriasisRecruitingPhase 2InventisBio Co., LtdNCT07489885Written as D-2570 Tablet
- A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque PsoriasisRecruitingPhase 3InventisBio Co., LtdNCT07326813Written as D-2570 Tablet
- A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)RecruitingPhase 2InventisBio Co., LtdNCT07311200Written as D-2570
- A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic ArthritisRecruitingPhase 2InventisBio Co., LtdNCT07315061Written as D-2570
- Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque PsoriasisRecruitingPhase 3InventisBio Co., LtdNCT07130604Written as D-2570
- Healthy Volunteer StudyActive, not recruitingPhase 1InventisBio Co., LtdNCT07270783Written as D-2570
- A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 2InventisBio Co., LtdNCT07035041Written as D-2570
- Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy SubjectsCompletedPhase 1InventisBio Co., LtdNCT07275775Written as D-2570
- Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque PsoriasisCompletedPhase 2InventisBio Co., LtdNCT06278350Written as D-2570